Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program

Study Identifier
P13-566
CT.gov Identifier
NCT01662336
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Human Immunodeficiency Virus (HIV)
    • Study Drug
  • Lopinavir / ritonavir
    • Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Subject is HIV-positive * On treatment with LPV/r or currently initiated on treatment with LPV/r. * Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel. * Willing to be enrolled in the Kaletra Adherence Support Assistance (KASA) program. * Prescribed LPV/r as part of his/her treatment by the treating physician.
    Exclusion Criteria:
    * Not willing to sign an informed consent. * In the opinion of the treating physician is unlikely to be available for the 12-month follow-up duration of the study. * Is currently participating in a clinical trial of an investigational product. * Not willing to participate in the KASA program.

    Protocol Summary

    The overall purpose of the study was to describe the real-life adherence, effectiveness and safety of the Kaletra Adherence Support Assistance (KASA) Program in human immunodeficiency virus (HIV)-positive patients who were receiving treatment with lopinavir / ritonavir (LPV/r; Kaletra®) in Canada.

    Study Locations

    No locations found.